Belmatoug N - Search Results

1

A prospective study of bone marrow hematopoietic and mesenchymal stem cells in type 1 Gaucher disease patients.

Lecourt S, Mouly E, Freida D, Cras A, Ceccaldi R, Heraoui D, Chomienne C, Marolleau JP, Arnulf B, Porcher R, Caillaud C, Vanneaux V, Belmatoug N, Larghero J. Lecourt S, et al. Among authors: belmatoug n. PLoS One. 2013 Jul 25;8(7):e69293. doi: 10.1371/journal.pone.0069293. Print 2013. PLoS One. 2013. PMID: 23935976 Free PMC article.

2

[Gaucher's disease ].

Belmatoug N, Caubel I, Stirnemann J, Billette de Villemeur T. Belmatoug N, et al. J Soc Biol. 2002;196(2):141-9. J Soc Biol. 2002. PMID: 12360743 Review. French.

3

[French results of enzyme replacement therapy in Gaucher's disease].

Schaison G, Caubel I, Belmatoug N, Billette de Villemeur T, Saudubray JM. Schaison G, et al. Among authors: belmatoug n. Bull Acad Natl Med. 2002;186(5):851-61; discussion 861-3. Bull Acad Natl Med. 2002. PMID: 12412377 French.

4

Parkinsonism in Gaucher's disease type 1: ten new cases and a review of the literature.

Kraoua I, Stirnemann J, Ribeiro MJ, Rouaud T, Verin M, Annic A, Rose C, Defebvre L, Réménieras L, Schüpbach M, Belmatoug N, Vidailhet M, Sedel F. Kraoua I, et al. Among authors: belmatoug n. Mov Disord. 2009 Jul 30;24(10):1524-30. doi: 10.1002/mds.22593. Mov Disord. 2009. PMID: 19513999 Review.

5

[Gaucher disease and pregnancy].

Belmatoug N, Heraoui D. Belmatoug N, et al. Presse Med. 2009 Dec;38 Suppl 2:2S17-23. doi: 10.1016/S0755-4982(09)73663-2. Presse Med. 2009. PMID: 20304300 French. No abstract available.

6

A French experience of type 3 Gaucher disease: Phenotypic diversity and neurological outcome of 10 patients.

Kraoua I, Sedel F, Caillaud C, Froissart R, Stirnemann J, Chaurand G, Flodrops H, Tari S, Gourfinkel-An I, Mathieu S, Belmatoug N, Billette de Villemeur T, Mignot C. Kraoua I, et al. Among authors: belmatoug n. Brain Dev. 2011 Feb;33(2):131-9. doi: 10.1016/j.braindev.2010.02.005. Epub 2010 Mar 21. Brain Dev. 2011. PMID: 20307947

7

Impact of imiglucerase on the serum glycosylated-ferritin level in Gaucher disease.

Stirnemann J, Boutten A, Vincent C, Mekinian A, Heraoui D, Fantin B, Fain O, Mentré F, Belmatoug N. Stirnemann J, et al. Among authors: belmatoug n. Blood Cells Mol Dis. 2011 Jan 15;46(1):34-8. doi: 10.1016/j.bcmd.2010.10.014. Epub 2010 Nov 16. Blood Cells Mol Dis. 2011. PMID: 21084203

8

[Gaucher disease].

Stirnemann J, de Villemeur TB, Heraoui D, Belmatoug N; Comité d'évaluation du traitement de la maladie de Gaucher. Stirnemann J, et al. Among authors: belmatoug n. Rev Prat. 2011 Feb;61(2):165-8. Rev Prat. 2011. PMID: 21618759 French. No abstract available.

9

Bone marrow microenvironment in an in vitro model of Gaucher disease: consequences of glucocerebrosidase deficiency.

Lecourt S, Vanneaux V, Cras A, Freida D, Heraoui D, Herbi L, Caillaud C, Chomienne C, Marolleau JP, Belmatoug N, Larghero J. Lecourt S, et al. Among authors: belmatoug n. Stem Cells Dev. 2012 Jan 20;21(2):239-48. doi: 10.1089/scd.2011.0365. Epub 2011 Oct 18. Stem Cells Dev. 2012. PMID: 21867425

10

The uptake of recombinant glucocerebrosidases by blood monocytes from type 1 Gaucher disease patients is variable.

Berger J, Stirnemann J, Bourgne C, Pereira B, Pigeon P, Heraoui D, Froissart R, Rapatel C, Rose C, Belmatoug N, Berger MG. Berger J, et al. Among authors: belmatoug n. Br J Haematol. 2012 Apr;157(2):274-7. doi: 10.1111/j.1365-2141.2011.08989.x. Epub 2012 Jan 9. Br J Haematol. 2012. PMID: 22224474 Free article. Clinical Trial. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

159 results

Search Page

Filters